The Company obtained NMPA's approval for TaurusOne® and TaurusElite®.

The Company started a multi-center clinical trial of the TaurusNXT® Transcatheter Aortic Valve Replacement System.

The Company completed the enrollment of the first subject for the First-in-human clinical trial of the TaurusWave®  Lithotripsy Valvuloplasty System.

The Company signed a cooperation development agreement with the U.S. company inQB8 Medical Technologies for transcatheter tricuspid valve replacements (TTVR).

The Company obtained NMPA's approval for Jasper® SS Intracranial Electrolytic Detachable Coil.、

The Company's Global Headquarters Base settled in Suzhou Industrial Park.